| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 5085 |
Provisional Schedule
| Committee meeting | 07 May 2024 |
| Expected publication | 17 July 2024 |
Project Team
| Project lead | Louise Jafferally |
Email enquiries
- If you have any queries please email TATeam4@nice.org.uk
| External Assessment Group | Newcastle NIHR TAR Team, Newcastle University |
Stakeholders
| Companies sponsors | BeiGene (zanubrutinib) |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Blood Cancer UK |
| Lymphoma Action | |
| Professional groups | Association of Cancer Physicians |
| British Society for Haematology | |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Associated public health groups | None |
| Comparator companies | Aspen Pharma (chlorambucil) (confidentiality agreement not signed, not participating) |
| Baxter Healthcare (cyclophosphamide, doxorubicin) (confidentiality agreement not signed, not participating) | |
| Celltrion Healthcare (rituximab) (confidentiality agreement not signed, not participating) | |
| Dr Reddy’s Laboratories (bendamustine) (confidentiality agreement not signed, not participating) | |
| Hospira (vincristine sulfate) (confidentiality agreement not signed, not participating) | |
| Medac GmBH (doxorubicin) (confidentiality agreement not signed, not participating) | |
| Pfizer (doxorubicin, rituximab) (confidentiality agreement not signed, not participating) | |
| Roche (rituximab) (confidentiality agreement not signed, not participating) | |
| Sandoz Ltd (cyclophosphamide, rituximab) (confidentiality agreement not signed, not participating) | |
| Seacross Pharmaceuticals (bendamustine, doxorubicin) (confidentiality agreement not signed, not participating) | |
| Zentiva (bendamustine) (confidentiality agreement not signed, not participating) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 26 September 2023 | Invitation to participate |
| 26 July 2023 - 23 August 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5085 |
| 26 July 2023 | In progress. Scoping commencing |
| 22 May 2023 | Please note that following on from an update received from the company, the appraisal has been scheduled back into the work programme. Therefore, we now anticipate that the appraisal will begin during late September 2023 when we will write to stakeholders about how they can get involved. The deadline for submissions is expected in approximately late November 2023. |
| 05 October 2022 | Suspended. Following on from information received from the company regarding the availability of evidence for this indication, NICE has decided to suspend this appraisal from its current work programme. NICE will continue to monitor any developments and will update interested parties as and when the situation changes. |
| 23 February 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual